Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

H3K4me2 ChIP-seq upon GSK inhibiton

ABSTRACT: We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers (H3K4me2), and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

ORGANISM(S): Homo sapiens

PROVIDER: GSE131321 | GEO | 2019/09/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148925 | GEO

ChIP-Seq for FOXA2 in PC3 cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148982 | GEO

ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148928 | GEO

ChIP-Seq for FOXA1 in LNCaP cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148926 | GEO

H3K4me2 ChIP-seq upon GSK inhibiton

Project description:H3K4me2 ChIP-seq upon GSK inhibiton

| PRJNA543247 | ENA

CUT & RUN analysis of H3K4me2 mark upon LSD1 inhibition

Project description:Lysine-specific demethylase 1 (LSD1) is a histone demethylase that promotes stemness and cancer cell survival, including in prostate cancer. LSD1 has been shown to perfrom catalytic independent function sto promote prostate cancer survival. Here, we tested the levels of LSD1's canonical target H3K4me2 upon LSD1 inhibition with SP2509 across the genome using CUT and RUN analysis.

2023-08-30 | GSE235211 | GEO

AR ChIP-seq with DHT induction and GSK treatment

Project description:The major pioneer factor activity of FOXA1 in PCa is to facilitate AR recruitment to androgen-regulated enhancers. Therefore, we hypothesized that the decreased FOXA1 binding and enhancer availability by LSD1 inhibition may result in the impairment of subsequent AR recruitment to enhancers. To globally test this hypothesis, we performed AR ChIP-seq in LNCaP cells treated with an LSD1 inhibitors. Consistent with previous reports, DHT treatment can dramatically induce AR binding to chromatin. Significantly, LSD1 inhibitor treatment in presence of DHT stimulation markedly decreased the total number of AR binding peaks and their intensity. We further assessed the impact of LSD1 inhibition on overall AR transcriptional output using RNA-seq data.

2019-09-29 | GSE114266 | GEO

RNA-Seq with DHT induction and/or GSK treatment at 24, 48 hrs and 2 weeks

2019-09-29 | GSE114267 | GEO

CUT & RUN analysis of H3K4me2 mark upon LSD1 inhibition

Project description:CUT & RUN analysis of H3K4me2 mark upon LSD1 inhibition

| PRJNA985560 | ENA

H3K4me2 profiling in C3H-10T1/2 preadipocytes [ChIP-seq]

Project description:By screening a collection of epigenetic compounds, we find that Lysine-Specific Demethylase 1 (LSD1) inhibitors repress brown adipocyte differentiation. RNAi-mediated Lsd1 knockdown shows similar effect, which can be rescued by expression of wild-type, but not catalytically inactive, LSD1. Furthermore, adenoviral Cre-mediated Lsd1 deletion in mice leads to inhibition of brown adipogenesis, validating the pivotal role of LSD1 in brown fat development in vivo. LSD1 represses gene expression by demethylating H3K4. To identify the target genes of LSD1 during BAT differentiation, we analyzed the H3K4me2 enrichment in preadipocyte.

2016-08-30 | GSE74901 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data